claim: de rational design of potent and resilient hace2 decoys to neutralize sars-cov-2.
evidence_1: we applied our design strategy to engineer, validate, and optimize de novo hace2 decoys to neutralize sars-cov-2 infection (fig.", "our pipeline allowed the design, validation, and optimization of de novo hace2 decoys to neutralize sars-cov-2.", "the high and specific binding affinity of the optimized de novo protein decoys translated into effective and specific in vitro neutralization of sars-cov-2 viral infection (fig.", "our pipeline allowed the design, validation, and optimization of de novo human angiotensin-converting enzyme 2 (hace2) decoys to neutralize severe acute respiratory syndrome coronavirus 2 (sars-cov-2)."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )